What is claimed is:

1. Use of an antibody that binds interferon gamma (IFNγ) in the manufacture of a medicament for the treatment of Macrophage Activation Syndrome (MAS) or secondary hemophagocytic lymphohistiocytosis (HLH) in a subject, wherein the antibody is to be administered at

i) a first dose of 6.0 mg/kg of the subject's body weight, and

ii) a second dose of 3.0 mg/kg to 10 mg/kg of the subject's body weight, and

wherein the antibody comprises: a variable heavy chain complementarity determining region 1 (VH CDR1) comprising the amino acid sequence of SYAMS (SEQ ID NO: 1); a variable heavy chain complementarity determining region 2 (VH CDR2) comprising the amino acid sequence of AISGSGGSTYYADSVKG (SEQ ID NO: 2); and a variable heavy chain complementarity determining region 3 (VH CDR3) comprising the amino acid sequence of DGSSGWYVPHWFDP (SEQ ID NO: 3); a variable light chain complementarity determining region 1 (VL CDR1) comprising the amino acid sequence of TRSSGSIASNYVQ (SEQ ID NO: 4); a variable light chain complementarity determining region 2 (VL CDR2) region comprising the amino acid sequence of EDNQRPS (SEQ ID NO: 5); and a variable light chain complementarity determining region 3 (VL CDR3) region comprising the amino acid sequence of QSYDGSNRWM (SEQ ID NO: 6).

2. The use of claim 1, wherein the antibody is to be administered at ii) a second dose of 3.0 mg/kg of the subject's body weight.

3. The use of claim 1, wherein the antibody comprises the heavy chain variable amino acid sequence to the amino acid sequence of SEQ ID NO: 47, and the light chain variable amino acid sequence to the amino acid sequence of SEQ ID NO: 48.

4. The use of claim 1, wherein the first dose of the antibody is to be administered over a period of 1 hour or more.

5. The use of claim 1, wherein the first dose of the antibody is to be administered over a period of 1 hour to 2 hours.

6. The use of claim 1, wherein the second dose is to be administered for a first treatment period, wherein the second dose is to be administered every three days after the first dose during the first treatment period.

7. The use of claim 6, wherein the first treatment period is about two weeks.

8. The use of claim 6, wherein the second dose is to be administered for a second treatment period after completion of the first treatment period.

9. The use of claim 8, wherein the second dose is to be administered twice weekly during the second treatment period.

10. The use of claim 8, wherein the second treatment period is about two weeks.

11. The use of claim 5, wherein a second dose is not administered for a second treatment period after the completion of the first treatment period.

12. The use of claim 11, wherein the first treatment period is about two weeks.

13. The use of claim 1, wherein the first dose and the second dose are to be administered intravenously.

14. The use of claim 1, wherein the antibody is in a pharmaceutical composition at a concentration of 5 mg/mL.

15. The use of claim 1, wherein the antibody is in a pharmaceutical composition at a concentration of 25 mg/mL.

16. The use of claim 1, wherein the antibody is to be administered as a pharmaceutical formulation and wherein the pharmaceutical formulation comprises L-histidine, L-histidine monohydrochloride, monohydrate, sodium chloride (NaCl), and Polysorbate 80, wherein the pH of the formulation is between pH 5.8 and pH 6.2.

17. The use of claim 1, wherein the subject has systemic Juvenile Idiopathic Arthritis (sJIA).

18. The use of claim 17, wherein the subject has shown inadequate response to high dose glucocorticoid treatment.

19. The use of claim 1, wherein the subject has an immune related disorder, such as an autoimmune disease or an inflammatory disorder.

20. The use of claim 1, wherein the subject has Adult-Onset Still's Disease (AOSD).

21. The use of claim 1, wherein the subject has Systemic Lupus Erythematosus (SLE).

22. The use of claim 1, wherein the subject is an adult subject.

23. The use of claim 1, wherein the subject is a pediatric subject.